KDR and neoplasm: As a small-molecule tyrosine kinase inhibitor selectively targeting VEGFR-2, apatinib inhibits endothelial cell proliferation, reduces tumor microvascular density, and promotes cell apoptosis via downregulation of the VEGF pathways to achieve suppression of tumor growth and recurrence (10, 11).